Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis

Area of Science:

• Hepatology
• Gastroenterology
• Internal Medicine

Background:

• The efficacy of human albumin infusion for overt hepatic encephalopathy (HE) in liver cirrhosis is not well-established.
• Cirrhosis is a significant health concern, and HE is a serious complication.

Purpose of the Study:

• To evaluate the role of human albumin infusion in preventing and treating overt HE in patients with liver cirrhosis.
• To assess the impact of albumin infusion on in-hospital mortality and overall outcomes in cirrhotic patients.

Main Methods:

• A retrospective study of cirrhotic patients (January 2010 - June 2014) with 1:1 propensity score matching.
• Systematic literature search and meta-analysis of studies on albumin infusion for overt HE management.
• Random-effect model meta-analysis to calculate odds ratios (OR).

Main Results:

• Albumin infusion significantly reduced the incidence of overt HE (4.20% vs. 12.70%) and in-hospital mortality (1.70% vs. 5.40%) in patients without pre-existing overt HE.
• In patients with overt HE, albumin infusion improved HE (84.60% vs. 68.10%) and decreased in-hospital mortality (7.70% vs. 19.80%).
• Meta-analysis showed a significant improvement in overt HE (OR=2.40, P=0.04) with albumin infusion, though prevention of overt HE did not reach statistical significance (OR=1.63, P=0.07).

Conclusions:

• Human albumin infusion may serve as a preventive measure against overt HE in cirrhosis.
• Albumin infusion appears to improve the severity of overt HE and reduce mortality in cirrhotic patients.
• The study suggests albumin infusion benefits cirrhotic patients irrespective of overt HE status.